Brain Scientific (OTCQB: BRSF), a health care company on a mission to modernize brain diagnostics with cutting-edge technologies, has developed and brought to market a pediatric-specific disposable EEG cap. The pediatric NeuroCap may aid in diagnosing autism and providing much needed information in treating pediatric epilepsy.
Autism is difficult to diagnose, yet the earlier it is discovered, the better the possibility of preventing some of the behaviors. A study published in the Scientific Reports Journal stated that EEGs can be used to accurately predict or rule out autism in children as young as three months (https://ibn.fm/t3KJq). One in fifty-nine children is diagnosed with autism by the time they are eight years old. It is one of the fastest-growing developmental disorders in the US, and the lifetime costs range anywhere from $1.4 to $2.2 million. (https://ibn.fm/XTPYG).
The CDC reports that there are approximately 470,000 children in the US with active epilepsy (https://ibn.fm/bs0Cv). Epilepsy does not present itself the same in every patient because there are many causes as well as many different types of seizures. This can make diagnosis challenging and EEGs are used in a supportive role combined with history, examinations and other tests (https://ibn.fm/Ja4Si).
When diagnosing children, the challenge comes in using ill-fitting bulky medical equipment designed for adults. The supply and availability of EEG testing in pediatrics are simply limited. Or it was until Brain Scientific decided to fill the gap and make easy-to-use disposable headsets for children and teens.
According to an article in Today’s Medical Developments (https://ibn.fm/CniU1), the team first approached the task intending to take the existing NeuroCap shrink it down to fit children and teens while also shortening the testing time from 30 minutes to 10 minutes. The process proved more challenging than expected in large part due to the pandemic.
Unable to meet in person, the team brainstormed through video conferencing and provided manufacturing instructions in pain-stacking detail. The manufacturer and one of the suppliers were forced to shut down at different times, both of which brought the process to a temporary halt.
Still, the team pushed forward, ensuring the timing was right, and they were the first to bring this product to the market. BRSF achieved the goal of creating a comfortable design in miniature and faster test results making the NeuroCap the perfect solution for pediatrics.
For more information, visit the company’s website at www.BrainScientific.com/Invest-Now.
NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information, please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
Approximately 20% of people in the U.S. live in a rural area, and they face…
On October 15, NETEC (National Emerging Special Pathogens Training & Education Center) announced a grant…
Patients are overwhelmed when they are diagnosed with glioblastoma, the most deadly primary brain cancer.…
Thermostable vaccine technology is considered a significant unmet need in epidemic preparedness. Soligenix has been…
Many existing cancer treatments, such as chemotherapy and radiation, don’t distinguish between cancer cells and…
A study whose findings were recently published has provided insights into the cost of treating…